Restoring balance at the neuromuscular junction

Neurology

Volumn 69, Issue 7, 2007, Pages 629-630

  Kaminski, Henry J ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHOLINERGIC RECEPTOR; EN101; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLINERGIC SYNAPSE; CLINICAL TRIAL; CONGENITAL MYASTHENIC SYNDROME; DRUG INHIBITION; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEAD INJURY; HUMAN; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PSYCHOLOGICAL BALANCE;

CLINICAL TRIALS, PHASE I; HUMANS; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; OLIGONUCLEOTIDES, ANTISENSE;

EID: 34547890688     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000269665.62498.5c     Document Type: Editorial

References (12)

1. Argov Z, McKee D, Agus S, et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 2007;69:699-700.
2. Soreq H, Seidman S. Acetylcholinesterase-new roles for an old actor. Nat Rev Neurosci 2001;2:294-302.
3. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 2003;17:214-222.
4. Moses H3rd, Martin JB. What should be done to improve the productivity of neurological research? Ann Neurol 2006;60:647-651.
5. Agrawal S, Zhang X, Lu Z, et al. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol 1995;50:571-576.
6. Dove A. Antisense and sensibility. Nat Biotechnol 2002;20:121-124.
7. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-355.
8. Tamm I, Wagner M. Antisense therapy in clinical oncology: preclinical and clinical experiences. Mol Biotechnol 2006;33:221-238.
9. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America [see comments] Neurology 2000;55:16-23.
10. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64:1968-1970.
11. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116:2843-2854.
12. Keesey J. Myasthenia gravis. An illustrated history. Roseville, CA: Publisher's Design Group, 2002.